System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Peter Malfertheiner is an expert in Gastroenterology at LMU Klinikum (Germany). Peter Malfertheiner has authored 1,255 publications, the most recent in 2026, and is an investigator in 14 clinical trials. SLR score: 4,245 (community average: 125). How the SLR is computed.

LeadR Profile

Peter Malfertheiner LMU Klinikum Germany
4 245 ScienceLeadR Reputation 4245

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Pharmacy - Infectiology - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1987 - 2026
Source: PubMed

LMU Klinikum

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1255

Citations

Citations: 63 196 1st author: 125 Last author: 568 Unique author: 41

Main journals

Gastroenterology 140
Dig Dis 90
Z Gastroenterol 56
Aliment Pharmacol Ther 54
Gut 41

Best Journals

N Engl J Med 6
Lancet 4
Gastroenterology 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Editorial: H. pylori Guidelines: To Implement and How-That Is the Question. Authors' Reply.
PMID 42598776 — pharmacology, therapeutics		Aliment Pharmacol Ther20260
Saccharomyces boulardii as a Probiotic Supplement in Helicobacter pylori Eradication Therapy: A Meta-analysis.
PMID 42470702 — helicobacter pylori, helicobacter, saccharomyces boulardii, drug-related side effects and adverse reactions, saccharomyces, probiotics, therapeutics		J Gastrointestin Liver Dis20260
Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real-World Practice.
PMID 42310251 — helicobacter pylori, helicobacter, antimicrobial stewardship, pharmacology, therapeutics, drug resistance		Aliment Pharmacol Ther20264
Performance and reproducibility of Pylori DuoTect® in a high Helicobacter pylori prevalence Latin American population.
PMID 42177123 — research design, helicobacter pylori, helicobacter, histology, prevalence, urease		J Microbiol Immunol Infect20260
Bone mineral density does not predict overall survival in patients with advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.
PMID 42054252 — carcinoma, hepatocellular, digestive system diseases, non-alcoholic fatty liver disease, sorafenib, therapeutics, bone density		Dig Dis20260

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Director: 1

By phase:

Phase 3 5
Phase 2 4
N/A 3
Phase 1 1
Phase 4 1

By status:

Completed 11
Unknown 2
Recruiting 1

By type:

Interventional 11
Observational 3

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS